Spruce Biosciences Ends Tildacerfont Trials for Rare Disorder

Spruce⁤ Biosciences Halts ⁤Tildacerfont Trials⁣ for Rare Genetic Disorder, Stock Plummets

Spruce Biosciences, Inc. ⁣(SPRB) announced Tuesday ⁣the discontinuation of its Phase 2b CAHmelia-204 and Phase 2 CAHptain-205 clinical trials evaluating tildacerfont as a treatment for congenital adrenal hyperplasia (CAH).⁣ The decision comes after‍ the CAHmelia-204 ‍trial failed to meet its primary efficacy endpoint.

CAH is⁤ a rare genetic⁢ disorder affecting the adrenal glands, leading to hormone deficiencies. Spruce’s tildacerfont aimed to reduce the need for glucocorticoid (GC) replacement therapy in CAH patients.

“In the interim,the CAHmelia-204 and CAHptain-205 clinical trials⁢ will be discontinued,and we ⁣will be winding ⁢down spruce’s investment in tildacerfont for the ⁣treatment of CAH as we conserve ‍financial resources and ⁤look to maximize shareholder value,” said Javier Szwarcberg,CEO of Spruce.

The‍ CAHmelia-204 trial, which enrolled 100 adults with classic CAH, did not achieve its primary⁤ goal of reducing daily GC⁢ dose from baseline at week ⁢24. While the 200mg QD‍ dose of tildacerfont showed a‍ placebo-adjusted‍ reduction in GC dose,it was not statistically meaningful.

The CAHptain-205 trial,evaluating tildacerfont in pediatric and ‍adult CAH patients,showed ⁤a⁤ trend of larger reductions ⁤in androstenedione (A4) levels with higher doses. Though, the ⁢trial was not designed to assess efficacy.

Tildacerfont was generally ⁣safe and well-tolerated in both trials, with no serious adverse events⁤ reported.

Following the announcement, SPRB stock plummeted⁢ 23.40% to $0.41 in premarket trading Wednesday.

Looking Ahead:

Spruce Biosciences’ decision to halt tildacerfont advancement for CAH marks ‍a significant setback for the ⁢company and its investors. The company will‍ now focus on conserving ⁣resources and exploring other strategic options to maximize shareholder⁤ value.

Hope Fades for CAH Treatment as Spruce Biosciences Halts Tildacerfont Trials

[City, State] – Spruce Biosciences,⁢ Inc. has announced the ⁢discontinuation of its Phase 2b clinical trials evaluating tildacerfont for the‍ treatment of congenital adrenal hyperplasia (CAH). The ⁢decision follows the failure of the CAHmelia-204 trial ‍too reach its⁣ primary efficacy endpoint.

“In the interim, the ⁢CAHmelia-204 and ⁤CAHptain-205 clinical trials will be discontinued, and we will be winding down spruce’s ⁣investment ⁣in tildacerfont for the treatment of CAH as we conserve financial resources and look to ⁣maximize⁢ shareholder value,” said Javier Szwarcberg, CEO⁣ of Spruce.

The CAHmelia-204 trial, involving 100 adults with classic CAH, aimed to reduce daily glucocorticoid (GC) dose from baseline at week 24. While the ⁢200mg QD dose showed a reduction‍ in GC dose ‍compared to placebo, it was not statistically meaningful.

The CAHptain-205 trial, which‍ included pediatric and adult CAH patients, observed a trend of larger reductions in androstenedione (A4) levels at higher doses of tildacerfont. However, the trial was not designed to ⁤assess efficacy.

Tildacerfont was generally well-tolerated in both trials, with no serious adverse events reported.

Following this announcement, Spruce Biosciences’ stock (SPRB) experienced a sharp decline of 23.40% in premarket trading Wednesday, ⁣dropping to $0.41.

This setback marks a significant challenge for both Spruce Biosciences and the CAH community, leaving many wondering about the future of this potential treatment.